Background: The application of genomic technologies to patient tumor samples identified groups of signaling pathways which acquire activating mutations. Some cancers are dependent on these mutations and the aberrant proteins resulting from these mutations can be targeted by novel drugs which can eradicate the cancer. Methods: We used www.cbioportal.org to determine the frequency of ERBB mutations in solid tumors. We then determined the sensitivity of a panel of cell lines to clinically available PI3K inhibitors. Using proliferation and apoptosis assays as well as functional interrogation with reverse phase protein arrays we demonstrated the impact of targeting ERBB-mutant cancers with the combination of a PI3K inhibitor and the pan-HER family inhibitor afatinib. Results: In over 14,000 patients we found that 12% of their tumors have an ERBB family gene mutation (EGFR, ERBB2, ERBB3 and ERBB4). In cancers not commonly associated with HER family protein overexpression, such as ovarian, endometrial, melanoma and head and neck cancers (n = 2116), we found that ERBB family mutations are enriched, occurring at rates from 14% to 34% and commonly co-occur with PIK3CA mutations. Importantly, we demonstrate that ERBB family mutant cancers are sensitive to treatment with PI3K inhibitors. Finally we show that the combination of afatinib and copanlisib represents a novel therapeutic strategy for patients whose cancers harbor both ERBB family and PIK3CA mutation. Conclusions: We demonstrate that ERBB family mutations are common in cancers not associated with overexpression or amplification of HER family proteins. These ERBB family mutant cancers are sensitive to treatment with PI3K inhibitors, and when combined with pan-HER inhibitors have synergistic antiproliferative effects.
Introduction
The application of genomic technologies to tumors has found certain signaling pathways commonly acquire activating mutations in a variety of cancers. In some cases, cancers are dependent on these mutations and the resulting aberrant proteins can be targeted by novel drugs. This has led to a paradigm shift in cancer therapy, from choosing nonselective cytotoxic drugs to targeted therapies, where the molecular and genetic characteristics of the tumor are used to select a particular therapy. 1 Some tumors thus contain mutations within oncogenes or tumor suppressor genes that predict responses to targeted anticancer therapies. Examples include epidermal growth factor receptor (EGFR) mutations which are found in up to 15% of non-small cell lung cancers and are targetable by EGFR inhibitors (erlotinib and gefitinib). 2 However, while considerable progress has been made in treatment options for some cancer types based on targeted therapies, only a minority of patients with cancer have tumors with targetable molecular aberrations. Therefore, we need to augment these successes
Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers
with therapies that target alternate molecular aberrations and signaling pathways.
The four erb-B receptor tyrosine kinase family members [ERBB1 (EGFR), ERBB2 (HER2), ERBB3 (HER3) and ERBB4 (HER4)] (ERBBfamily) encode type I transmembrane proteins that share common structural properties and are activated by either homo-or hetero-dimerization with other ERBB family members. 3, 4 Dimerization results in activation of signal transduction pathways such as the PI3K/AKT and MAPK/ERK pathways, which are associated with oncogenesis and cancer therapy resistance. 3 Recent studies found that somatic ERBB2, ERBB3 and ERBB4 mutations occur in breast, colorectal and gastric cancers, [5] [6] [7] with ERBB3 mutations being associated with an aggressive phenotype. Modeling experiments of ERBB4 mutations have shown their ability to alter the signaling properties of the HER family members. Our study identifies that ERBB family mutations which are commonly enriched in cancers which are not HER2 amplified are targetable with PI3K inhibitors. We also demonstrate that cancers which have both an ERBB family and PIK3CA mutation are most sensitive to the combination of the pan-HER kinase inhibitor afatinib and the PI3K inhibitor copanlisib, identifying a new therapeutic strategy for treating patients who harbor ERBB family mutations.
Results

ERBB family mutations occur in more than 10% of analyzed tumors from www.cbioportal.org
Individual ERBB family (EGFR, ERBB2, ERBB3 and ERBB4) somatic mutations were detected in 12% of cancers identified from www.cbioportal. org. Our analysis included 14,539 cases of cancer from 81 different datasets (Table 1) , and found PIK3CA mutations occur in 13% of patient tumors, 14% have an ERBB family gene mutation, while 2% have a co-occurring PIK3CA and ERBB family gene mutation [ Figure 1 (a)].
Mutations in the PIK3CA gene are some of the most commonly occurring targetable mutations detected in solid tumors. Using PIK3CA mutation frequency (13% of tumors analyzed) as a benchmark, we restricted the studies we analyzed to cases where ERBB family mutations were detected at a comparable or higher frequency. In these studies we found somatic ERBB family mutations in 29% of cases (both alone and co-occurring with PIK3CA mutations), whilst PIK3CA mutations alone occur in 15% of cancers [Figure 1(b) ]. We also found that ERBB family mutations and PIK3CA mutations co-occur in 6% of these cancers. Our findings demonstrate that even in cancer subtypes not commonly associated with HER family protein overexpression such as ovarian, endometrial, melanoma and head and neck cancer that ERBB family mutations are enriched and can cooccur with PIK3CA mutations.
Somatic ERBB family mutations are enriched in specific cancer subtypes
We selected datasets for further analysis which were enriched for ERBB family mutations (>12% ERBB family mutated, comparable to 13% of PIK3CA mutation rate) and included the largest numbers of patients (Table 2) .
We found that somatic ERBB family mutations occur between a rate of 14.7% in head and neck squamous cell carcinoma and 27.7% in skin cutaneous melanoma. Analysis of ERBB family mutations reveals that over 20% of bladder urothelial carcinoma (n = 33/130), colorectal adenocarcinoma (n = 130/619), esophageal carcinoma (n = 38/185), pan-lung cancer (n = 271/1144), stomach adenocarcinoma (n = 98/289) and skin cutaneous melanomas (n = 101/366) have an ERBB family mutation which does not co-occur with a PI3KCA mutation. Analysis of the datasets for which somatic ERBB family mutations are enriched (>12%) reveals that somatic PIK3CA mutation rates vary between 1.4% in melanoma and 41.7% in uterine corpus endometrioid carcinoma (Table 3) . We found in cervical squamous cell carcinomas and endocervical adenocarcinomas and uterine corpus endometrioid carcinomas that over 20% of these cancers had a PIK3CA mutation which occurred without an ERBB family mutation.
We finally found that co-occurring ERBB family and PIK3CA mutations can be identified in this subset of patient tumors at rates ranging between 1.5% in pan-lung cancer patients and 11.3% in uterine corpus endometrioid carcinomas. Interestingly, in bladder urothelial carcinomas, stomach adenocarcinomas and uterine corpus endometrioid carcinomas more than 8% of patient tumors have a co-occurring PIK3CA and ERBB family mutation. Guo et al. 10 Bladder urothelial carcinoma (BGI) Ciriello et al. 23 Breast Muzny et al. 26 Colorectal adenocarcinoma (TCGA) 29 Esophageal adenocarcinoma (Broad) Agrawal et al. 33 Head and neck squamous cell carcinoma (Johns Hopkins) Lin et al. 37 Nasopharyngeal carcinoma (Singapore) Gerlinger et al. 42 Multiregion sequencing of clear cell Li et al. 48 Gallbladder carcinoma (Shanghai) Grasso et al. 61 Prostate adenocarcinoma, metastatic ( Li et al. 73 Cutaneous squamous cell carcinoma The predominant mutated ERBB family members identified in bladder urothelial carcinomas were ERBB2 (9%) and ERBB3 (11%) ( Table 2 ). In the pan-lung cancers these were EGFR (10%) and ERBB4 (9%) whilst in the stomach adenocarcinomas these were ERBB3 (11%) and ERBB4 (13%). Finally ERBB4 (16%) was the most commonly mutated in the skin cutaneous melanomas.
ERBB family mutations and PIK3CA mutations commonly co-occur in patient tumors
In patients with bladder urothelial carcinomas PIK3CA mutations significantly co-occur with ERBB3 (p = 0.035) and EGFR (p = 0.039), whilst in cervical squamous cell carcinomas and endocervical adenocarcinomas PIK3CA mutations significantly co-occur with ERBB2 (p = 84 , pictilisib (23 cell lines) 85 and gedatolisib (17 cell lines) 86 representing multiple cancer types identified that cells with a PIK3CA mutation were 6.45 fold more Table 5 .
Comparison of sensitivity to PI3K inhibitors copanlisib (C) 84 , pictilisib (P) 85 and gedatolisib (G) 86 in a panel of cell lines with multiple histologies, based on their ERBB family or PIK3CA mutational status. sensitive to copanlisib (n = 8, p = 0.046), 2.14 fold more sensitive to pictilisib (n = 4, p = 0.025) and 6.27 fold more sensitive to gedatolisib (not significant, n = 5) than those cell lines which were wild type for PIK3CA (Table  5 ). This result demonstrates the importance of PIK3CA mutations as a biomarker of response to PI3K inhibitors.
Interestingly, we also demonstrated that cell lines with only an ERBB family mutation are more sensitive to PI3K inhibition with copanlisib (p = 0.039) and gedatolisib (p = 0.002) relative to those cells which are WT for both PIK3CA and ERBB family genes (Figure 2 ). However, we also found cell lines with an ERBB family mutation (both ERBB family Mut and PIK3CA/ERBB family Mut cells) were 8.39 fold more sensitive to copanlisib (n = 22, p = 0.005), 2.86 fold more sensitive to pictilisib (n = 10, p = 3 × 10 −4 ), and 6.33 fold more sensitive to gedatolisib (n = 5, p = 0.048) than cell lines which were ERBB family/PIK3CA WT (Table 6 ). There were no significant differences between the copanlisib and pictilisib halfmaximal inhibitory concentration IC 50 s in cells with only an ERBB family mutation versus either only PIK3CA-mutated cells or cell lines with both an ERBB family and a PIK3CA mutation.
Cell lines which are ERBB family/PIK3CA mutant are sensitive to the combination of afatinib and copanlisib
We tested copanlisib alone and in combination with the pan-HER inhibitor afatinib in a panel of cell lines (Table 7) . Combination index (CI) values were calculated and identified that cell lines which are ERBB family Mut/PIK3CA Mut are most sensitive to the combination of copanlisib and afatinib (Table 8 ; Figure 3 ). CI at effective dose (ED) 75 demonstrates that cell lines which are ERBB family Mut/PIK3CA Mut are borderline significantly more likely to have a synergistic response to the combination of afatinib and copanlisib (p = 0.064). The combination of copanlisib and afatinib also has efficacy in SW620, LoVo and C2BBE1 cell lines. SW620 and LoVo cell lines are both KRAS mutant whilst C2BBE1 cells have an Mammalian target of rapamycin (mTOR) mutation. These specific mutations could account for the sensitivity of the cell line to the combination of drugs.
Copanlisib and afatinib induce different proteomic responses in cell lines with different ERBB family/PIK3CA mutational status
We conducted a reverse phase protein array (RPPA) analysis of copanlisib and afatinib tested alone and in combination in four cell lines representing the different mutational groups. Antibodies selected were chosen to represent multiple nodes on the PI3K/AKT, MAPK/ERK and apoptotic signaling pathways. Drug concentrations and the duration of treatment were chosen to reflect an effective dose of drug which would inhibit effector signaling pathways but ensure that observed proteomic effects were specific to the drugs and were not compromised by an associated cell death signal. 
Afatinib and copanlisib induce apoptosis in PIK3CA-mutant and ERBB family Mut/PIK3CA Mut cell lines
Copanlisib [125 nM (p = 0.02) and 250 nM (p = 0.037)] significantly increases levels of apoptosis in the HT29 cell line (PIK3CA Mut; Figure 5 ), however the combination of afatinib and copanlisib does not significantly increase apoptosis in HT29 compared with copanlisib alone. In H1975 cells (ERBB family/PIK3CA Mut) neither copanlisib nor afatinib alone induces a significantly greater level of apoptosis than the vehicle control, however the combination of copanlisib (120 nM) and afatinib (500 nM) does increase apoptosis (p = 0.037) relative to that achieved using either copanlisib or afatinib alone. In H1975 cells (ERBB family/PIK3CA Mut) the combination of copanlisib (120 nM) and afatinib (500 nM) was significantly more likely to increase apoptosis relative to the cell lines that are WT for both mutations (p = 0.006) or ERBB family mutant (p = 0.001) or PIK3CA mutant (p = 0.04). In support of this result we found in the RPPA data that treatment of H1975 cells (ERBB family/PIK3CA Mut) with the combination of afatinib and copanlisib significantly increases the expression of the pro-apoptotic family member BID (Figure 6 ), whilst there is a close to significant increase in BAK expression (p = 0.063) and a decrease in expression of the antiapoptotic family member MCL-1 (p = 0.087). The combined evidence points towards the combination of afatinib and copanlisib producing a proapoptotic signal in H1975 cells, which is not observed in the remaining cell lines tested.
Discussion
The ERBB network which includes the four receptors of the ERBB pathway EGFR, HER2, HER3 and HER4 function through dimerization to form a layered network which has been implicated in the development and treatment of cancer. 87,88 ERBB family mutations have been shown in our studies and by others to be enriched in classically non-ERBB-family amplified cancers. 6, 89, 90 However, we also found that ERBB family mutations co-occur with PIK3CA mutations in endometrial, colorectal, ovarian and stomach cancers. This therefore indicates that patients who have an ERBB family or PIK3CA mutation are significantly more likely to have an activated PI3K/AKT signaling pathway. Table 6 . Comparison of sensitivity to PI3K inhibitors copanlisib (C) 84 , pictilisib (P) 85 and gedatolisib (G) 86 Copanlisib, gedatolisib and pictilisib are PI3K inhibitors which have shown preclinical activity in the treatment of many cancer types, especially those which are PIK3CA mutated. 84 were as sensitive to PI3K inhibition as those cell lines which are PIK3CA mutated. We therefore demonstrated that PI3K inhibitors could be effective for the treatment of patients who not only harbor PIK3CA mutations but also ERBB family mutations.
Afatinib, a pan-HER inhibitor, is currently undergoing phase I and II testing in several cancers, including, breast, glioblastoma and head and neck cancers. 95 Afatinib which has not been tested clinically in combination with PI3K inhibitors provides a rational approach for targeting cancers in which the PI3K pathway may be activated by ERBB family mutation. In fact when we combined afatinib and copanlisib together we found that cell lines which harbored both an ERBB family mutation and a PIK3CA mutation had the greatest antiproliferative response to the combination treatment. We also demonstrated that two-thirds of cell lines that are ERBB family mutant, but were WT for PIK3CA, had synergistic inhibition of proliferation to the combination of afatinib and copanlisib. Moreover it is important to note that copanlisib alone as well as in combination with afatinib showed good effectiveness in KRASmutated SW620 cells (ERBB family/PIK3CA WT), underlining the potentially beneficial effects of this combination in the treatment of cancers with upregulated PI3K or MAPK signaling. 94 We selected four cell lines representing the different mutational groups for further functional analysis of the proteomic and apoptotic impact of combining afatinib and copanlisib in vitro. These cell lines were selected as they demonstrated the most profound response to the combination therapy. They all represented cell lines which were RAS mutation negative, so as to avoid the impact of activated RAS signaling which may provide confounding effects on PI3K/AKT signaling.
We demonstrated by apoptosis assays and proteomic studies that the antiproliferative effect can be associated with the ability of copanlisib and afatinib to effectively inhibit both PI3K/AKT and MAPK/ ERK signaling in H1975 cells (ERBB family/ PIK3CA Mut). We confirmed that dual inhibition of PI3K and MAPK signaling pathways in H1975 cells (ERBB family/PIK3CA Mut) induced a proapoptotic proteomic signal. We confirmed using FACS analysis that treatment of H1975 cells with the combination of copanlisib and afatinib resulted in a significant increase in apoptosis, which was not observed in the other cell lines. This is an interesting observation as despite ERBB-family-mutant cell lines being sensitive to the combination of afatinib and copanlisib, it was only in the ERBB family/PIK3CA mutant cell lines that the combination produced a proapoptotic impact, likely indicating that the combination was cytostatic and not cytotoxic in cell lines which harbor an ERBB family mutation only.
The combination of afatinib and copanlisib may be an effective treatment strategy for patient tumors which have both an ERBB family and PIK3CA mutation. A limitation of this targeted combinatorial approach may be the underlying heterogeneity of the tumors, when cancers with low ERBB family/ PIK3CA gene mutational frequency may be less responsive to the combination. We believe that fully translational clinical studies are required to determine how much of an issue this will be in treating these patients. These studies can be used to interrogate and ascertain modes of acquired and innate resistance in these cancer types. However, our study clearly highlights the ability to identify and stratify patients based on the presence of ERBB family mutations, with patients whose tumors cofeature PIK3CA mutations the most likely to gain robust antitumor responses. These findings support the initiation of a clinical trial testing PI3K inhibitors in ERBB-mutant/PIK3CA-mutant cancers.
Materials and methods
ERBB family mutational data analysis
All data mining was performed using cBioPortal and data analysis was performed on TCGA datasets in July 2016. The full list of datasets analyzed for this study is available in Table 1 . The results used herein are in part based upon data generated by the TCGA Research Network: http://cancergenome. nih.gov/ and from www.cbioportal.org. 8, 96 The data analyzed include mutational data from 14,539 different cancer samples in 31 cancer types. All searches including co-occurrence analysis were performed according to the cBioPortal's online instructions. Ethics approval and informed consent were not required for this study as the data were already in the public domain. mutational status of cell lines used in this study was taken from the CCLE which are publicly available from Broad Institute. BAY80-6946 (Copanlisib) a PI3K inhibitor (PI3Ki) was obtained under MTA from Bayer Pharmaceuticals (Germany) and 10 mM stocks were prepared in dimethyl sulfoxide (DMSO) and 5% triflouroacetic acid. Afatinib was acquired from Sequoia Chemicals (United Kingdom) and 10 mM stocks were prepared in DMSO.
Cell culture
Proliferation assays
For all cell lines no P/S was added to media during proliferation assays. 1 × 10 3 cells/well were seeded in 96-well plates, apart from HCT116 which was seeded at 2 × 10 2 cells/well, C2BBE1 which was seeded at 2 × 10 3 cells/well, H1975 which was seeded at 5 × 10 2 cells/well and CL-14 and MFE280 which were seeded at 5 × 10 3 cells/ well. Plates were incubated overnight at 37°C to allow cells to adhere. Drugs were added to the plates at specific concentrations and incubated at 37°C. Copanlisib and afatinib were combined at a ratio of 1:4 in all cell lines apart from T47D, KLE and MFE280 which were combined at a ratio of 1:16. Following 5-day incubation, during which control cells attained 80-90% confluence, all media was removed from the plates, and washed twice with phosphate-buffered saline (PBS). Proliferation was measured using the acid phosphatase assay as previously described. 97 A minimum of triplicate biological assays were carried out for each experiment. Reverse phase protein array analysis RPPA analysis of the in vitro data was performed as previously described by us. 98,99 RPPA analysis was carried out using triplicate biological replicates, and the data were normalized by protein loading using the entire antibody panel. The full list of antibody endpoints used in the RPPA experiments, including the company from which it was purchased and the relevant catalogue number, host species and dilution at which it was used, is given in Table 9 . 
Apoptosis assay
Calculation for fold change in protein expression phosphorylation
The formula to calculate fold change is calculated according to the error of propagation:
The formula to calculate the standard deviation according to the error of propagation is:
(http://ipl.physics.harvard.edu/wp-uploads/ 2013/03/PS3_Error_Propagation_sp13.pdf). Statistical analysis IC 50 and CI values at ED 75 were calculated using CalcuSyn software (BioSoft, United Kingdom). 
